Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MTNR1B | P49286 | 1/20 | 0.39 |
| ▸ | BCHE | P06276 | 1/20 | 0.38 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.37 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.37 |
| ▸ | ADRB2 | P07550 | 1/20 | 0.37 |
| ▸ | ADRB1 | P08588 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.37 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.36 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL990798 | 0.82 | BCHE (0.57) | MTNR1BBCHEKMT2A | |
| SCHEMBL3346743 | 0.82 | BCHE (0.57) | MTNR1BBCHEKMT2A | |
| SCHEMBL1680336 | 0.82 | BCHE (0.57) | MTNR1BBCHEKMT2A | |
| Hydrochloric Acid SCHEMBL987382 | 0.81 | BCHE (0.56) | MTNR1BBCHEKMT2A | |
| Acetic Acid SCHEMBL3169809 | 0.77 | MTNR1B (0.54) | MTNR1BBCHEHCRTR1HCRTR2KMT2A | |
| Acetic Acid SCHEMBL990742 | 0.77 | MTNR1B (0.54) | MTNR1BBCHEHCRTR1HCRTR2KMT2A | |
| SCHEMBL12200036 | 0.76 | BCHE (0.47) | MTNR1BBCHEHCRTR1HCRTR2KMT2A | |
| Hydrochloric Acid SCHEMBL3654652 | 0.74 | BCHE (0.47) | MTNR1BBCHEHCRTR1HCRTR2ADRB2 | |
| SCHEMBL6391182 | 0.72 | ADRB2 (0.53) | BCHEADRB2KMT2AMEN1 | |
| SCHEMBL4026249 | 0.72 | BCHE (0.58) | BCHEKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2451281-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | Merck Sharp & Dohme Corp. (US) | 2012-05-16 | — | — | EP | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | MERCK SHARP & DOHME CORP. | 2012-04-26 | — | — | US | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
| WO-2011005636-A1 | TETRAHYDRONAPTHYRIDINE OREXIN RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2011-01-13 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120101106-A1 | Tetrahydronapthyridine Orexin Receptor Antagonists | HCRTR2, HCRTR1, OXTR | MTNR1B 29/4885BCHE 909/4885HCRTR1 2/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.